TVTXTravere Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 22878
Ticker: TVTX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2003-07-23
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: TVTX

Detail

Enriched 2026-08-14 20:47

Market cap: $5,859,268,857.12
Shares outstanding (class): 94,261,082
Shares outstanding (weighted): 94,261,082
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 497
Location: SAN DIEGO, CA
Homepage: https://www.travere.com
Description: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Market cap and share counts drift.

Funds holding this security

147 funds · 152 positions · $575.56M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$87.63M	0.00%	2,949,373 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$85.07M	1.14%	2,863,192 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$59.94M	0.08%	2,017,358 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$42.55M	0.82%	1,432,164 NS	FIGI
Janus Henderson Triton Fund JANUS INVESTMENT FUND	—	$32.68M	0.63%	1,100,064 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$29.70M	0.04%	999,551 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$20.04M	0.25%	674,600 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$18.77M	0.15%	631,730 NS	FIGI
Janus Henderson Venture Fund JANUS INVESTMENT FUND	—	$17.90M	0.58%	602,435 NS	FIGI
Nomura Small Cap Growth Fund IVY FUNDS	—	$12.51M	1.27%	421,116 NS	FIGI
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$11.14M	0.11%	374,846 NS	FIGI
abrdn Healthcare Investors —	—	$10.49M	0.92%	353,234 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$9.90M	0.11%	333,349 NS	FIGI
Driehaus Small Cap Growth Fund Driehaus Mutual Funds	—	$7.40M	0.64%	249,132 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$7.19M	0.09%	242,014 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERTVTX
FIGI_COMPOSITEBBG000P9D6W9
FIGI_SHARE_CLASSBBG001SL72C5
CIK0001438533
ISINUS89422G1076
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare diseases, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.